Identification of target genes of oncogenic transcription factors

Proceedings of the Society for Experimental Biology and Medicine

Volumn 222, Issue 1, 1999, Pages 9-28

  Boyd, Kathryn E ^a   Farnham, Peggy J ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR;

CANCER GENETICS; DNA SEQUENCE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR CLONING; MULTIGENE FAMILY; NONHUMAN; ONCOGENE C MYC; SHORT SURVEY; TRANSCRIPTION REGULATION;

MAMMALIA;

EID: 0032825860     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1373.1999.09992.x     Document Type: Short Survey

References (89)

1. Struhl K. Helix-turn-helix, zinc-finger, and leucine-zipper motifs for eukaryotic transcriptional regulatory proteins. TIBS 14:137-140, 1989.
2. Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood 90:489-519, 1997.
3. Gelmann EP, Psallidopoulos MC, Papas TS, Dalla Favera R. Identification of reciprocal translocation sites within the c-myc oncogene and immunoglobulin mu locus in a Burkitt lymphoma. Nature 306:799-803, 1984.
4. Schwab M. Amplification of N-myc as a prognostic marker for patients with neuroblastoma. Semin Cancer Biol 4:13-18, 1993.
5. Li W, Fan J, Hochhauser D, Banerjee D, Zielinski Z, Almasan A, Yin Y, Kelly R, Wahl GM, Bertino JR. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA 92:10436-10440, 1995.
6. Dittmer J, Nordheim A. Ets transcription factors and human disease. Biochim Biophys Acta 1377:F1-F11, 1998.
7. Chang CH, Scott GK, Kuo WL, Xiong X, Suzdaltseva Y, Park JW, Sayre P, Erny K, Collins C, Gray JW, Benz CC. ESX: A structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene 14:1617-1622, 1997.
8. Golub TR, McLean T, Stegmaier K, Carroll M, Tomasson M, Gilliland DG. The tel gene and human leukemia. Biochim Biophys Acta 1288:M7-M10, 1996.
9. Hiebert SW, Sun W, Davis JN, Golub T, Shurtleff S, Buijs A, Downing JR, Grosveld G, Roussel MF, Gilliland DG, Lenny N, Meyers S. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol 16:1349-1355, 1996.
10. Braun BS, Frieden R, Lessnick SL, May WA, Denny CT. Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis. Mol Cell Biol 15:4623-4630, 1995.
11. Facchini LM, Penn LZ. The molecular role of Myc in growth and transformation: Recent discoveries lead to new insights. FASEB J 12:633-651, 1998.
12. Asker CE, Magnusson KP, Piccoli SP, Andersson K, Klein G, Cole MD, Wilman KG. Mouse and rat B-Myc share amino acid sequence homology with the c-Myc transcriptional activator domain and contain a B-Myc specific carboxy terminal region. Oncogene 11:1963-1969, 1995.
13. Wenzel A, Schwab M. The mycN/max protein complex in neuroblastoma: Short review. Eur J Cancer 31:516-519, 1995.
14. Barrett J, Birrer MJ, Kato GJ, Dosaka-Akita H, Dang CV. Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells. Mol Cell Biol 12:3130-3137, 1992.
15. McMahon SB, Van Buskirk HA, Dugan KA, Copeland TD, Cole MD. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 94:363-374, 1998.
16. Sakamuro D, Elliot KJ, Wechsler-Reya R, Prendergast GC. BIN1 is a novel Myc-interacting protein with features of a tumour suppressor. Nat Genet 14:69-76, 1996.
17. Bush A, Mateyka M, Dugan K, Obaya A, Adachi S, Sedivy J, Cole M. c-Myc null cells misregulate cad and godd45 but not other proposed c-Myc targets. Genes Dev 12:3797-3802, 1998.
18. Li L-H, Nerlov C, Prendergast G, MacGregor D, Ziff EB. c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. EMBO J 18:4070-4079, 1994.
19. Roy AL, Carruthers C, Gutjahr T, Roeder RG. Direct role for myc in transcription initiation mediated by interaction with TFII-I. Nature 365:359-361, 1993.
20. Desbarats L, Gaubatz S, Eilers M. Discrimination between different E-box-binding proteins at an endogenous target gene of c-Myc. Genes Dev 10:447-460, 1996.
21. Xiao Q, Claassen G, Shi J, Adachi S, Sedivy J, Hann SR. Transactivation-defective c-MycS retains the ability to regulate proliferation and apoptosis. Genes Dev 12:3803-3808, 1998.
22. Davis AC, Wims M, Spotts GD, Hann SR, Bradley A. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev 7:671-682, 1993.
23. Moens CB, Auerbach AB, Conlon RA, Joyner AL, Rossant J. A targeted mutation reveals a role for N-Myc in branching morphogenesis in the embryonic lung. Genes Dev 6:691-704, 1992.
24. Charron J, Malynn BA, Fisher P, Stewart V, Jeannotte L, Goff SP, Robertson EJ, Alt FW. Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene. Genes Dev 6:2248-2257, 1992.
25. Sawai S, Shimono A, Wakamatsu Y, Palmes C, Hanaoka K, Kondoh H. Defects of embryonic organogenesis resulting from targeted disruption of the N-myc gene in the mouse. Development 117:1445-1455, 1993.
26. Stanton BR, Perkins AS, Tessarollo L, Sassoon DA, Parada LF. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev 6:2235-2247, 1992.
27. Sirito M, Lin Q, Deng JM, Behringer RR, Sawadago M. Overlapping roles and asymmetrical cross-regulation of the USF proteins in mice. Proc Natl Acad Sci U S A 95:3758-3763, 1998.
28. Moroy T, Fisher P, Guidos C, Ma A, Zimmerman K, Tesfaye A, DePinho R, Weissman I, Alt FW. IgH enhancer deregulated expression of L-myc: Abnormal T-lymphocyte development and T-cell lymphomagenesis. EMBO J 9:3659-3666, 1990.
29. Dildrop R, Ma A, Zimmerman K, Hsu E, Tesfaye A, DePinho R, Alt FW. IgH enhancer-mediated deregulation of N-Myc gene expression in transgenic mice: Generation of lymphoid neoplasias that lack c-Myc expression. EMBO J 8:1121-1128, 1989.
30. Rosenbaum H, Webb E, Adams JM, Cory S, Harris AW. N-Myc transgene promotes B lymphoid proliferation, elicits lymphomas, and reveals cross-regulation with c-Myc. EMBO J 8:749-755, 1989.
31. Slansky JE, Farnham PJ. Introduction to the E2F family: Protein structure and gene regulation. In: Farnham PJ, Ed. New York: Springer-Verlag, pp1-30, 1996.
32. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 12:2245-2262, 1998.
33. Nevins JR. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ 9:585-593, 1998.
34. Bremner R, Cohen BL, Sopta M, Hamel PA, Ingles CJ, Gallie BL, Phillips RA. Direct transcriptional repression by pRB and its reversal by specific cyclins. Mol Cell Biol 15:3256-3265, 1995.
35. Ferreira R, Magnaghi-Jaulin L, Robin P, Harel-Bellan A, Trouche D. The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase. Proc Natl Acad Sci U S A 95:10493-10498, 1998.
36. Parr MJ, Manome Y, Tanaka T, Wen P, Kufe DW, Kaelin WGJ, Fine HA. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 3:1145-1149, 1997.
37. Adams PD, Kaelin WG. Transcriptional control of cell growth: The E2F gene family. In: Farnham PJ, Ed. Transcriptional Control of Cell Growth: The E2F Gene Family. New York: Springer-Verlag, pp79-93, 1995.
38. Pierce AM, Gimenez Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ, Johnson DG. Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc Natl Acad Sci U S A 95:8858-8863, 1998.
39. Pierce AM, Fisher SM, Conti DJ, Johnson DG. Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development. Oncogene 16:1267-1276, 1998.
40. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F1. Cell 85:537-548, 1996.
41. Field SJ, Tsai F-Y, Kuo F, Zubiaga AM, Kaelin WG, Jr., Livingston DM, Orkin SH, Greenberg ME. E2F1 functions in mice to promote apoptosis and suppress proliferation. Cell 85:549-561, 1996.
42. Lindeman GJ, Dagnino L, Gaubatz S, Xu Y, Bronson RT, Warren HB, Livingston DM. A specific, nonproliferative role for E2F5 in choroid plexus function revealed by gene targeting. Genes Dev 12:1092-1098, 1998.
43. Solomon DL, Amati B, Land H. Distinct DNA binding preferences for the c-Myc/Max and Max/Max dimers. Nucleic Acids Res 21:5372-5376, 1993.
44. Bendall AJ, Molloy PL. Base preferences for DNA binding by the bHLH-Zip protein USF: Effects of MgCl2 on specificity and comparison with binding of Myc family members. Nucleic Acids Res 22:2801-2810, 1994.
45. Boyd KE, Farnham PJ. Myc versus USF: Discrimination at the cad gene is determined by core promoter elements. Mol Cell Biol 17:2529-2537, 1997.
46. Fisher F, Crouch DH, Javaraman PS, Clark W, Gillespíe DA, Goding CR. Transcription activation by Myc and Max: Flanking sequences target activation to a subset of CACGTG motifs in vivo. EMBO J 12:5075-5082, 1993.
47. Blackwell TK, Huang J, Ma A, Krstzner L, Alt F, Eisenman R, Weintraub H. Binding of Myc proteins to canonical and noncanonical DNA sequences. Mol Cell Biol 13:5216-5224, 1993.
48. Hann SR, Dixit M, Sears RC, Sealy L. The alternatively initiated c-Myc proteins differentially regulate transcription through a noncanonical DNA binding site. Genes Dev 8:2441-2452, 1994.
49. Nye JA, Petersen JM, Gunther CV, Jonsen MD, Graves BJ. Interaction of murine Ets-1 with GGA-binding sites establishes the ETS domain as a new DNA-binding motif. Genes Dev 6:975-990, 1992.
50. Thompson CG, Wang C-Y, Ho I-C, Bohjanen PR, Petryniak B, June CH, Miesfeldt S, Zhang L, Nabel GJ, Karpinski B, Leiden JM. cis-Acting sequences required for inducible interleukin-2 enhancer function bind a novel Ets-related protein, Elf-1. Mol Cell Biol 12:1043-1053, 1992.
51. Shore P, Whitmarsh AJ, Bhaskaran R, Davis RJ, Waltho JP, Sharrocks AD. Determinants of DNA-binding specificity of ETS-domain transcription factors. Mol Cell Biol 16:3338-3349, 1996.
52. Magnaghi-Jaulin L, Masutani H, Robin P, Lipinski M, Harel-Bellan A. SRE elements are binding sites for the fusion protein EWS-FLI-1. Nucleic Acids Res 24:1052-1058, 1996.
53. Liu N, Lucibello FC, Engeland K, Muller R. A new model of cell cycle-regulated transcription: Repression of the cyclin A promoter by CDF-1 and antirepression by E2F. Oncogene 16:2957-2963, 1998.
54. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci U S A 94:7245-7250, 1997.
55. Tao Y, Kassatly R, Cress WD, Horowitz JM. Subunit composition determines E2F DNA-binding site specificity. Mol Cell Biol 17:6994-7007, 1997.
56. Buttice G, Duterque-Coquillaud M, Basuyaux JP, Carrere S, Kurkinen M, Stehelin D. Erg, an Ets family member, differentially regulates human collagenase1 (MMP1) and stromelysin1 (MMP3) gene expression by physically interacting with the Fos/Jun complex. Oncogene 13:2297-2306, 1996.
57. Shaw PE, Schröter H, Nordheim A. The ability of a ternary complex to form over the serum response element correlates with serum inducibility of the human c-fos promoter. Cell 56:563-572, 1989.
58. Boyd KE, Wells J, Gutman J, Bartley SM, Farnham PJ. c-Myc target gene specificity is determined by a post-DNA-binding mechanism. Proc Natl Acad Sci U S A 95:13887-13892, 1998.
59. Luo X, Sawadogo M. Functional domains of the transcription factor USF2: Atypical nuclear localization signals and context-dependent transcriptional activation domains. Mol Cell Biol 16:1367-1375, 1996.
60. Kollmar R, Sukow KA, Sponagle SK, Farnham PJ. Start site selection at the TATA-less carbamoyl-phosphate synthase (glutamine-hydrolyzing)/aspartate carbamoyltransferase/dihydroorotase promoter. J Biol Chem 269:2252-2257, 1994.
61. Watanabe G, Albanese C, Lee RJ, Reutens A, Vairo G, Henglein B, Pestell RG. Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1. Mol Cell Biol 18:3212-3222, 1998.
62. Karlseder J, Rotheneder H, Wintersberger E. Interaction of Sp1 with the growth and cell cycle-regulated transcription factor E2F. Mol Cell Biol 16:1659-1667, 1996.
63. Slansky JE, Li Y, Kaelin WG, Farnham PJ. A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Mol Cell Biol 13:1610-1618 [author's correction: 13:7201], 1993.
64. Fry CJ, Slansky JE, Farnham PJ. Position-dependent transcriptional regulation of the murine dihydrofolate reductase promoter by the E2F transactivation domain. Mol Cell Biol 17:1966-1976, 1997.
65. Lin S-Y, Black AR, Kostic D, Pajovic S, Hoover CN, Azizkhan JC. Cell cycle-regulated association of E2F1 and Sp1 is related to their functional interaction. Mol Cell Biol 16:1668-1675, 1996.
66. De Francesco L. Taking the measure of the message. The Scientist 12:20-21, 1998.
67. Marshall A, Hodgson J. DNA chips: An array of possibilities. Nature Biotechnology 16:27-31, 1998.
68. DeRisi J, Penland L, Brown PG, Bittner ML, Meltzer PS, Ray M. Chen Y, Su YA, Trent JMG. Use of cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 14:457-460, 1996.
69. Lockhart D, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, Brown EL. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nature Biotechnology 14:1675-1680, 1996.
70. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci U S A 90:7804-7808, 1993.
71. Eilers M, Schirm S, Bishop JM. The Myc protein activates transcription of the α-prothymosin gene. EMBO J 10:133-141, 1991.
72. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M. Conditional expression of N-Myc in human neuroblastoma cells increases expression of α-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13:809-812, 1996.
73. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257:967-971, 1992.
74. Hubank M, Schatz DG. Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res 22:5640-5648, 1994.
75. Lisitsyn N, Lisitsyn N, Wigler M. Cloning the differences between two complex genomes. Science 259:946-951, 1993.
76. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science 270:484-487, 1995.
77. Benvenisty N, Leder A, Kuo A, Leder P. An embryonically expressed gene is a target for c-Myc regulation via the c-Myc-binding sequence. Genes Dev 6:2513-2523, 1992.
78. 1 serum response genes and identification of a subset regulated by conditional myc expression. Mol Biol Cell 5:375-388, 1994.
79. Lewis BC, Shim H, Li Q, Wu CS, Lee LA, Maity A, Dang CV. Identification of putative c-Myc-responsive genes: Characterization of rcl, a novel growth-related gene. Mol Cell Biol 17:4967-4978, 1997.
80. Shim H, Dolde C, Lewis BC, Wu C-S, Dang G, Jungmann RA, Dalla-Favera R, Dang CV. c-Myc transactivation of LDH-A: Implications for tumor metabolism and growth. Proc Natl Acad Sci USA 94:6658-6663, 1997.
81. Robinson L, Panayiotakis A, Papas TS, Kola I, Seth A. Ets target genes: Identification of Egr1 as a target by RNA differential display and whole genome PCR techniques. Proc Natl Acad Sci U S A 94:7170-7175, 1997.
82. Lawlor ER, Lim JF, Tao W, Poremba C, Chow CJ, Kalousek IV, Kovar H, MacDonald TJ, Sorensen PH. The Ewing tumor family of peripheral primative neuroectodermal tumors expresses human gastrin-releasing peptide. Cancer Res 58:2469-2476, 1998.
83. May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet 17:495-497, 1997.
84. Arvand A, Bastians H, Welford SM, Thompson AD, Ruderman JV, Denny CT. EWS/FLI1 upregulates mE2-C, a cyclin-selective ubiquitin conjugating enzyme involved in cycin B destruction. Oncogene 17:2039-2045, 1998.
85. Kim JH, Hui P, Yue D, Aycock J, Leclerc C, Bjoring AR, Perkins AS. Identification of candidate target genes for EVI-1, a zinc finger oncoprotein, using a novel selection strategy. Oncogene 17:1527-1538, 1998.
86. Grandori C, Mac J, Siëbelt F, Ayer DE, Eisenman R. Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo. EMBO J 15:4344-1357, 1996.
87. Walter J, Biggin MD. Measurement of in vivo DNA binding by sequence-specific transcription factors using UV cross-linking. Methods 11:215-224, 1997.
88. Orlando V, Strutt H, Paro R. Analysis of chromatin structure by in vivo formaldehyde cross-linking. Methods 11:205-214, 1997.
89. Cohen-Kaminsky S, Maouche-Chretien L, Vitelli L, Vinit M-A, Blanchard I, Yamamoto M, Peschle C, Romeo P-H. Chromatin immunoselection defines a TAL-1 target. EMBO J 17:5151-5160, 1998.